Key facts
- Avammune Therapeutics’s last known valuation is $33.0M (May 2025).
- It has raised $18.5M; the latest was Later Stage VC ($12.0M) in May 2025.
- Notable investors include JITO Incubation & Innovation Foundation, Shastra VC, IvyCap Ventures, The Chennai Angels, 1Crowd — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Avammune Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Avammune Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avammune Therapeutics
Developer of non-nucleotide small-molecule inhibitors designed for the treatment of cancer and infectious diseases. The company develops a multimodal approach that employs a combination of engineered viruses and small molecules to modulate the pathway to treat cancer, enabling patients to harness their immune systems.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2017
- Employees
- 13
- Website
- avammune.com/
- Ownership
- Privately Held (backing)
Avammune Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avammune Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avammune Therapeutics in its N-PORT filings yet. We sweep new filings monthly.